GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Question] Ireland — has anyone got a straight answer on shortage list — 32 comments in the full submission. View in context.
611
c/compounding·submitted 1 year ago by u/lukas_vermeulen

[Question] Ireland — has anyone got a straight answer on shortage list

Questionbranch of 7 comments

The title is the whole question — Ireland — has anyone got a straight answer on shortage list — but here is why I am asking. Paid noticeably more at one clinic than another for what turned out to be the same facility behind both. Switched between two compounded preparations and the concentration on the label was…

Read the full submission and all 32 comments →

This branch

7 comments, started 1 year ago
u/yannick_petrov25 points·1 year ago·edited

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

replysharereportpermalink
u/swirl_dont_shakereconstitution9 points·1 year ago

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

replysharereportpermalink
u/lukas_vermeulenOP0 points·1 year ago

What concentration is on the label, and does it match what you were expecting?

replysharereportpermalink
u/lukas_vermeulenOP1 point·1 year ago

What is the beyond-use date and what is it based on?

replysharereportpermalink
[removed]16 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/tobias_vukovic8 points·1 year ago·edited

That figure is the starting material purity, not the finished preparation potency. Two different tests.

replysharereportpermalink
u/runa_grimaldi4 points·1 year ago

That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.

replysharereportpermalink

← back to the whole thread

About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/compounding
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/formulary_fighteru/usp_appendixu/quiet_moderatoru/prior_auth_pain
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →